
1. elife. 2018 dec 27;7. pii: e41081. doi: 10.7554/elife.41081.

transcriptomic analysis reveals reduced transcriptional activity malaria
parasite plasmodium cynomolgi progression dormancy.

bertschi nl(#)(1), voorberg-van der wel a(#)(2), zeeman am(2), schuierer s(1),
nigsch f(1), carbone w(1), knehr j(1), gupta dk(3), hofman so(2), van der werff
n(2), nieuwenhuis i(2), klooster e(2), faber bw(2), flannery el(3), mikolajczak
sa(3), chuenchob v(3), shrestha b(1), beibel m(1), bouwmeester t(1),
kangwanrangsan n(4), sattabongkot j(5), diagana tt(3), kocken ch(2), roma g(1).

author information: 
(1)novartis institutes biomedical research, novartis pharma ag, basel,
europe.
(2)department parasitology, biomedical primate research centre, rijswijk, 
netherlands.
(3)novartis institute tropical diseases, novartis pharma ag, emeryville,
united states.
(4)department pathobiology, faculty science, mahidol university, bangkok,
thailand.
(5)mahidol vivax research unit, faculty tropical medicine, mahidol university,
bangkok, thailand.
(#)contributed equally

relapses plasmodium dormant liver hypnozoites compromise malaria eradication
efforts. new radical cure drugs urgently needed, yet vast gap in
knowledge hypnozoite biology impedes drug discovery. previously unraveled
the transcriptome 6 7 day-old p. cynomolgi liver stages, highlighting
pathways associated hypnozoite dormancy (voorberg-van der wel et al., 2017).
we extend findings transcriptome profiling 9 10 day-old liver 
stage parasites, thus revealing first time maturation dormant 
stage time. although progression dormancy leads 10-fold decrease 
transcription expression 840 genes, including genes associated with
housekeeping functions, show pathways involved quiescence, energy
metabolism maintenance genome integrity remain prevalent pathways
active mature hypnozoites.

Â© 2018, bertschi et al.

doi: 10.7554/elife.41081 
pmcid: pmc6344078
pmid: 30589413  [indexed medline]

conflict interest statement: nb, ss, fn, wc, jk, dg, ef, sm, vc, bs, mb, tb,
td, gr employed and/or shareholder novartis pharma ag. av, az, sh, nv, in, 
ek, bf, nk, js, ck competing interests declared

